Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07057024 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression

Study acronym: ReViPSY
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Start date changed from estimate of Sep 2025 to Feb 12, 2026v2 Show 6 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2027 to Feb 2028
    • Study completion date: Dec 2028 to Feb 2029
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site contact updated
    • Publications: details revised at 3 of 9 entries
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms. As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities. The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD). The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.
Trial Details
NCT Number NCT07057024
Lead Sponsor Etablissement Public de Santé Barthélemy Durand
Collaborators: Aix Marseille Université, Institut National de la Santé Et de la Recherche Médicale, France, Hopital Paul Brousse
Conditions
(from sponsor)
Psychiatric Disorders (Diagnosis)
Related terms Bipolar Disorder, Depression, Disease, Mental Disorders, Schizophrenia
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov